The urokinase receptor (uPAR) is a clinically relevant target for novel biological therapies. We have previously rescued oncolytic measles viruses fully retargeted against human (MV-h-uPA) or murine (MV-m-uPA) uPAR. Here, we investigated the in vivo effects of systemic administration of MV-m-uPA in immunocompetent cancer models. MV-m-uPA induced in vitro cytotoxicity and replicated in a receptor-dependent manner in murine mammary (4T1) and colon (MC-38 and CT-26) cancer cells. Intravenous administration of MV-m-uPA to 4T1 tumor-bearing mice was not associated with significant clinical or laboratory toxicity. Higher MV-N RNA copy numbers were detected in primary tumors, and viable viral particles were recovered from tumor-bearing tissues only. Non-tumorbearing organs did not show histological signs of viral-induced toxicity. Serum anti-MV antibodies were detected at day 14 of treatment. Immunohistochemistry and immunofluorescence studies confirmed successful tumor targeting and demonstrated enhanced MV-m-uPA-induced tumor cell apoptosis in treated compared with control mice. Significant antitumor effects and prolonged survival were observed after systemic administration of MV-m-uPA in colon (CT-26) and mammary (4T1) cancer models. The above results show safety and feasibility of uPAR targeting by an oncolytic virus, and confirm significant antitumor effects in highly aggressive syngeneic immunocompetent cancer models.
INTRODUCTION
The oncolytic virotherapy field has significantly expanded in the last decade, and recently, several novel viral vectors have reached late phase clinical evaluation. 1 Among the novel oncolytic viruses under development, the Edmonston vaccine strain of measles virus (MV-Edm) is a promising one, whose safety and efficacy are well established. 2, 3 In ovarian cancer, MV-CEA has demonstrated clinical safety after intraperitoneal administration. 4 Recombinant, non-targeted oncolytic MVs are currently being evaluated in brain tumors, multiple myeloma and mesothelioma. 1 Redirecting MV-Edm's target specificity provides potential advantages over non-targeted viral agents, by enhancing the selectivity, and therefore, safety and efficacy of the oncolytic virus. [5] [6] [7] [8] However, the majority of published recombinant MV vectors are targeted against receptors that are present in human, but not host (rodent) tissues. This limits the ability to fully characterize issues such as safety, selectivity and antitumor efficacy of targeted oncolytic MVs in syngeneic models with an intact immune system. In order to obtain preclinical data more predictive of the potential virus-tumor-host interactions that may occur in humans, it is critical to develop viral agents directed at targets that are expressed in human and murine tumors and tissues in a similar manner.
The urokinase receptor (uPAR) is a glycosylphosphoinositol anchored cell surface receptor whose role in tumor progression and angiogenesis is well recognized. 9 It is overexpressed in a variety of human and murine cancers, and its presence has been associated with metastatic potential and poor prognosis. [10] [11] [12] [13] [14] [15] [16] [17] During normal conditions, tissue expression of uPAR is very limited, and restricted to during active tissue remodeling, injury and inflammation. 9, [17] [18] [19] [20] [21] [22] [23] Genetic and biological anti-uPAR strategies have shown to induce potent antitumor effects, [24] [25] [26] [27] and agents like anti-uPAR antibodies or uPAR targeted nanoparticles successfully target tumors and micrometastases in vivo, without affecting non-tumor-bearing organs. 28, 29 This makes uPAR as a promising target for oncolytic viral therapies.
MV-uPA is a novel oncolytic measles virus fully retargeted against uPAR. 30 MV-uPA was engineered by displaying the aminoterminal fragment of either human (MV-h-uPA) or mouse (MV-m-uPA) urokinase in the C-terminus of a CD46 and SLAM 'blind' MV-H glycoprotein (H AALS ). 30 The fully retargeted viruses were shown to bind to human or murine uPAR-expressing cells in a receptor and species-specific manner. In our previous report, we demonstrated antitumor effects of MV-h-uPA against human breast cancer xenografts. 30 MV-m-uPA (which targets murine uPAR) offers the unique opportunity for in vivo characterization of the safety and antitumor effects of a fully retargeted oncolytic MV in syngeneic models of cancer, where the target is naturally expressed by tumors and tissues, similar to the human situation.
In this study, the safety, biodistribution, organ toxicity, targeting and antitumor effects of MV-m-uPA in syngeneic, immunocompetent cancer models were investigated. As uPAR is a highly relevant human and murine tumor target, results from our in vivo studies will be useful to predict safety and efficacy during preclinical and clinical development of uPAR targeted oncolytic viral therapies.
RESULTS uPAR-dependent in vitro cytotoxicity and viral replication in murine cancer cells To assess differences in MV-m-uPA-induced cytotoxicity in murine cancer cells with different levels of uPAR expression, receptor levels were determined in murine colon cancer (MC-38 and CT-26), murine mammary cancer (4T1) and melanoma (B16F10) cells. 4T1, MC-38 and CT-26 had increased uPAR expression compared with B16F10 cells, which had markedly less expression (Figure 1a TCID 50 ) intravenously, and were killed at 2, 5 and 28 days after treatment. No significant toxicity or treatment-related deaths were observed throughout the study. No changes in feeding behavior or activity were observed, nor were signs of physical distress or neurotoxicity observed in treated mice. Tumors and organs were harvested for viral biodistribution and toxicity studies. Total RNA was extracted from frozen specimens and quantitative reverse transcriptase-PCR for MV-N mRNA was performed. Significantly more viral RNA was detected in tumors compared with other organs at days 2 and 5 after treatment ( Figure 2 ). There was a sizeable increase in viral copy numbers in tumor tissues at day 5 compared with day 2 (P ¼ 0.0622, Figure 2a ), strongly suggesting viral replication in the tumor. Conversely, levels of viral RNA decreased in the majority of non-tumor-bearing organs from days 2 to 5 after treatment (Figures 2b-f, Supplementary Figure 3) . At day 5 of treatment, tumor viral RNA copy numbers were significantly higher (Po0.003) than that for all other organs. Of note, viral RNA in the livers of one of the treated animals reached levels observed in primary tumors (6.5 Â 10 5 TCID 50 ) at day 2, but the levels decreased by day 5 (Figure 2c) . By day 28 after virus administration, compared with day 2, there were significantly fewer copies of the viral RNA detectable in the lungs (P ¼ 0.0014), liver (P ¼ 0.0060), heart (Po0.001) and kidney (Po0.0001) of the MV-m-uPA-treated animals.
Viremia and antibody production MV-m-uPA RNA was detected in the blood of treated animals at day 2, and levels significantly decreased at days 5, 14 and 28 after treatment (Figure 2h ). At day 28, viral RNA was detected in 2/5 mice in the blood at low levels. Viral RNA was detected in the urine of treated animals at day 2, but significantly decreased at days 5 and 28 of treatment (Figure 2g ). Serum from mice was obtained at days 7, 14 and 28 after treatment for determination of 
Laboratory parameters
At day 5, blood samples were obtained for complete blood count and clinical chemistry (liver and renal function) analysis. Hematology studies showed that both treated and untreated tumor-bearing mice had elevated white blood cell counts, with the treated mice having higher white blood cell counts than the controls (Table 1 ). In addition, lymphocyte percentages were decreased in both treated and control groups, albeit the degree of relative lymphopenia was greater in virus-treated mice. Calculated absolute lymphocyte counts, however, were not markedly different between the two groups (5651 Â 10 3 ml -1 in treated mice vs 5348 Â 10 3 ml -1 in untreated mice). Otherwise, no clinically significant differences were observed in other hematological or chemistry values in treated vs control mice. To determine if the increase in white blood cell counts was directly related to the virus treatment, a separate group of tumor-free mice were treated with MV-m-uPA as described above, and complete blood counts were performed. No changes in the white blood cells or lymphocytes were observed in tumor-free mice treated with the virus (Supplementary Table 1 ).
In vivo antitumor effects Next, the in vivo antitumor effects of systemic administration of MV-m-uPA were investigated. In vivo safety of uPAR retargeted measles virus Y Jing et al characterization of preclinical safety or virus-host interactions was limited by the use of either immunodeficient xenograft models, models where the target was not expressed by host tissues or immunocompetent models where targets were artificially expressed in murine cancer cells. Ideally, the retargeted oncolytic virus should be directed against targets that are biologically relevant and naturally expressed in murine cancers and tissues in a similar way as in humans. Under these conditions, data on safety, tissue distribution and tumor targeting may be more predictive of the human situation.
The uPAR is a clinically validated and biologically important target that is overexpressed in many human as well as murine cancers. 11, 13, 14, 28 Non-oncolytic viral strategies that target the uPAR have been shown to be tumor specific and to be associated with antitumor effects in vitro and in vivo. 24, 25, 28 We have previously shown that human uPAR retargeted viruses (MV-h-uPA) induce significant antitumor effects in a human breast cancer xenograft model in vivo, in immunodeficient mice. 30 The effects of this viral vector in syngeneic, immunocompetent cancer models have not been previously described.
In this study, we focused on characterizing the virus-tumorhost interactions in syngeneic cancer models using the murine uPAR retargeted MV (MV-m-uPA). We demonstrated uPARdependent in vitro cytotoxicity induced by MV-m-uPA, as well as successful in vitro viral replication in murine cancer cells that overexpress uPAR (4T1, CT-26, MC-38), whereas no efficacy was observed in murine melanoma cell lines (B16F10), which express low levels of uPAR.
Systemic administration of MV-m-uPA in immunocompetent mice bearing syngeneic mammary tumors was found to be safe and feasible. This was demonstrated both in the biodistribution studies (4T1 model), as well as the dose escalation studies in the efficacy studies (4T1 and CT-26 models). MV-m-uPA preferentially accumulates in tumor tissues after intravenous administration compared with other organs. The observation that viral RNA copy numbers increased in tumor tissues from days 2 to 5, while they decreased in other organs, as well as viable virus recovery in tumor tissues only strongly suggests tumor-selective viral replication. Tumor targeting by MV-m-uPA was also demonstrated by immunohistochemistry analysis of MV-N in treated, but not in control tumors (Figure 4c) .
Serum biochemistry studies did not show evidence of liver or renal toxicity (Table 1 ). The observation that white blood cell counts were elevated in treated and untreated tumor-bearing mice (Table 1 ), but not in treated non-tumor-bearing mice (Supplementary Table 1) suggests that changes in white blood cells may be secondary to tumor burden, and not directly due to the virus treatment. As expected in immunocompetent models, an antibody response was observed in treated mice at 14 days after systemic administration of MV-m-uPA.
Correlative histopathologic analysis of the organs where viral RNA was detected showed no signs of significant organ toxicity induced by the virus. The observation that the livers of some tumor-bearing mice treated with MV-m-uPA had higher viral RNA titers, viable virus (in 1/5 treated mice) and focal inflammatory changes can be explained by probable targeting by MV-m-uPA to liver micrometastases-which spontaneously develop in orthotopic 4T1 tumors-and not because of virus-induced hepatotoxicity. Lack of hepatotoxicity is supported by several lines of evidence, including lack of histological signs of liver injury in tumor-free mice The biological significance of the findings was demonstrated by significant antitumor effects and prolonged survival in the very aggressive murine models of mammary carcinoma (4T1) and murine colon carcinoma (CT-26). TUNEL assays showed increased in vivo apoptosis in tumors treated with the retargeted virus compared with controls. This finding provides further in vivo validation of prior in vitro studies reporting that one mechanism of oncolytic measles virus cytotoxicity is induction of apoptosis. [35] [36] [37] Further studies are required, however, to elucidate the cellular, molecular and immunological mechanisms of MV-m-uPA-induced cytotoxicity in vitro and in vivo.
The in vivo antitumor effects (both antitumor response and survival) were more marked in the colon cancer than the mammary carcinoma model. The in vivo differences were correlated with the in vitro results (Figure 1) , where CT-26 cells were found to be more sensitive for viral infection and permissive for viral replication than 4T1 cells, although uPAR expression was similar between the two cell lines. These findings may reflect differences in cellular innate antiviral responses, or in oncogenic pathways, which may render some cancer cells less sensitive to the cytotoxic effects of oncolytic viruses. 38, 39 The in vitro and in vivo differences in sensitivity to MV-m-uPA between the two models (which grow in the same mouse strains -(Balb/c-)), offer the opportunity to investigate mechanisms of intrinsic resistance to this and other oncolytic measles viruses, and identify strategies to improve the virus' in vitro and in vivo antitumor effects.
The results presented above make this viral vector a very useful tool to better understand the virus-tumor-host interactions in vivo, for translational and clinical development of retargeted viral agents. The demonstration of safety and tumor targeting of MV-m-uPA in immunocompetent cancer will allow further studies that will exploit the abilities of this novel agent for preclinical development of uPAR targeted viral agents in general, and MV-uPA in particular. Current efforts are focused on characterization of the tumor-host-virus interactions in regards to changes in the innate and adaptive immunity induced by the virus, and development of strategies to improve the virus' antitumor efficacy in immune competent animals. As uPAR targeting is associated with important antitumor effects, our results will lead to development of other viral vectors retargeted against the uPAR.
In conclusion, this is the first report to our knowledge of safety, feasibility and antitumor efficacy of systemic administration of an oncolytic measles virus fully redirected to a naturally expressed, biologically relevant human and murine tumor target, in immunocompetent cancer models. The promising safety and antitumor activity of this novel viral agent warrant further studies and consideration for further clinical development of uPAR targeted oncolytic viral therapies.
MATERIALS AND METHODS

Virus preparation and cell culture
Construction of MV-m-uPA, virus rescue, propagation, titration, infection and in vitro cytopathic effects were performed as previously reported. 
Flow cytometry
Mouse uPA receptor expression was detected in cancer cell lines by flow cytometry, using a phycoerythrin-conjugated rat monoclonal anti-mouse uPAR (R&D Systems, Minneapolis, MN, USA), as previously described. 30, 41 Animal studies Animal studies were approved by Institutional Animal Care and Use Committee of University of Miami.
Mouse biodistribution and organ toxicity studies
In all, 8-to 10-week-old female Balb/c mice (Jackson Laboratories, Bal Harbor, ME, USA) were injected with 1 Â 10 5 4T1 cells in 50 ml phosphate-buffered saline (PBS) into the fifth mammary fat pad. When tumors reached a diameter of 0.7 cm, mice (five mice per group per time point) were treated with MV-m-uPA at a dose of 1.5 Â 10 6 TCID 50 (in 100 ml PBS) via tail vein every other day for two doses, or 100 ml PBS as control. At days 2, 5 and 28 after treatment, mice (n ¼ 5 per group) were killed. Tumors and major organs (brain, lung, heart, liver, spleen, pancreas, kidney and ovaries) were harvested for viral RNA determination and histopathology studies. At each time point, urine were obtained before killing and frozen ( À 80 1C). At days 2, 5, 14 and 28 after treatment, blood was collected by retro-orbital plexus puncture.
Additional studies were conducted to compare the effects of MV-m-uPA in the livers of tumor-bearing vs non-tumor-bearing mice. Three groups of mice (n ¼ 5) were established: (a) tumor-free Balb/c mice treated with MV-m-uPA, 1.5 Â 10 6 TCID 50 (in 100 ml PBS for two doses), (b) 4T1 tumorbearing Balb/c mice treated as above and (c) 4T1 tumor-bearing Balb/c mice treated with PBS. At days 5 after treatment, mice were killed and livers were removed and fixed in 10% neutral buffered formalin, paraffin embedded, sectioned at 5 mm and stained with hematoxylin and eosin for histological analysis by a veterinary pathologist. The presence of any lesions (inflammatory, necrotic, infectious, neoplastic, and so on) was assessed.
Characterization of MV-m-uPA's in vivo oncolytic effects in immunocompetent cancer murine models TCID 50 (1.66 Â 10 7 per dose Â 3). Tumor volume was measured twice a week and calculated with the following formula (width 2 Â length Â 0.5). Clinical signs of toxicity were closely monitored. Tumor-bearing animals were followed until they reached killing criteria (when tumor burden reached 10% of body weight, if tumor ulceration occurred or mice became moribund). To evaluate tumor targeting of the recombinant viruses after systemic administration, 4T1 mammary tumor model was established as above. Tumor-bearing mice (n ¼ 3) were treated with two intravenous injections of 1.5 Â 10 6 TCID 50 of MV-m-uPA, and tumors were resected after 72 h of the last injection, for immunohistochemistry studies for MV-N protein.
Viral RNA quantification
Total RNA was extracted from frozen specimens using the RNeasy tissue mini kit (for tumor, brain, lung, liver, spleen, pancreas, kidney and ovaries) or the RNeasy fibrous tissue mini kit (Qiagen, Valencia, CA, USA) for heart. RNA from blood samples was isolated using the QIAamp RNA blood mini kit. RNA from urine was isolated using the QIAamp viral RNA minikit (Qiagen), following the manufacturer's recommendations. Quantitative reverse transcriptase-PCR for MV-N(ucleoprotein) mRNA was performed as previously reported. 42 Hematology and chemistry analysis Whole blood and serum were harvested from mice at specific time points, and host toxicity was evaluated by assessment of changes in hematological and biochemical parameters using a Hemavet 1700 multispecies hematology analyzer (Drew Scientific, Dallas, TX, USA) and an Ortho Vitros 250 analyzer (Ortho-Clinical Diagnostics, Rochester, NY, USA), respectively.
Anti-MV antibody assay
Mice bearing 4T1 tumors were treated as described above, killed (n ¼ 3 per time point) at 7, 14 and 28 days after treatment and serum was collected for anti-MV antibody studies. The MV-specific IgG titer was measured by an indirect immunofluorescence test using MV antigen substrate slides (Bion Enterprises, Des Plaines, IL, USA) according to the manufacturer's instructions, and performed as described. 43, 44 The protocol was modified using goat anti-mouse IgG fluorescein isothiocyanate-conjugated antibodies (Invitrogen, Grand Island, NY, USA) for detection of murine antibodies.
Virus recovery
Tissues were weighed and homogenized in three volumes (w/v) of Opti-MEM utilizing mechanical crushing and a single freeze-thaw cycle. The supernatant was clarified by centrifugation and 10-fold serial dilutions of samples were prepared in Opti-MEM. Aliquots (50 ml) of each dilution were placed in 96-well plates containing Vero-his cells and TCID 50 titrations were performed. TCID 50 calculations were normalized per gram of tissue.
Immunohistochemistry studies
Tissue samples were collected and frozen, and cryostat sections were fixed in cold acetone for 10 min and endogenous peroxidase activity were quenched with 0.3% H 2 O 2 for 10 min. The slides were washed in PBS and incubated with biotinylated mouse anti-MV-nucleoprotein antibody (Chemicon International, Temecula, CA, USA) for 30 min at 37 1C. After washing in PBS, the slides were developed with VECTASTAIN ABC horseradish peroxidase kit (Vector Laboratories, Burlingame, CA, USA) and 3, 3, 9-diaminobenzidine (DAB) horseradish peroxidase substrate (Vector Laboratories) according to the manufacturer's instructions.
TUNEL assay
Apoptosis was detected with an in situ cell death detection kit (Roche Applied Science, Indianapolis, IN, USA), as previously described by us. 45 
Statistical analysis
The data in this study fell into three types: (1) continuous measures where only one observation was made on the experimental unit; (2) continuous measures where there were repeated observations, usually over time, where each experimental unit had multiple observations under different conditions; and, (3) time to survival after tumor transplant. The data in type 1 were analyzed using the analysis of variance and multiple linear and nonlinear regression. Subgroup comparisons were made after the overall analyses using the Student's t-test in single degree of freedom contrasts. Analyses were performed using SAS PROC GLM and SAS PROC REG statistical programs (SAS institute, Cary, NC, USA). The data from type 2 observations were analyzed using mixed model analysis of variances suitable for repeated measures. Single degree of freedom contrasts were performed between and within conditions, at specific times, and across time using the methods proposed by. 46 The survival data were analyzed using Kaplan-Meir stratified analyses in SAS PROC LIFETEST and the Cox Proportional Hazards model in SAS PROC PHREG. Statistical significance was set at P ¼ 0.05 with adjustments for multiple comparisons when appropriate.
